Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study. (21st July 2022)

• Record Type: Journal Article
• Authors: Ito, Katsuhiro; Kita, Yuki; Yokomizo, Akira; Miki, Jun; Yoshio, Yuko; Matsumoto, Hiroaki; Segawa, Takehiko; Karashima, Takashi; Nishiyama, Naotaka; Imai, Kazuto; Suekane, Shigetaka; Nagasawa, Seiji; Higashi, Shin; Nishiyama, Hiroyuki; Kitamura, Hiroshi; Kobayashi, Takashi
• Is Part Of: Cancer medicine. Volume 12:Number 3(2023)
• Page Start: 2325
• Page End: 2332
• Publication Date: 2022-07-21
• Subjects: carcinoma, transitional cell -- duration of therapy -- immune checkpoint inhibitors -- immunotherapy -- pembrolizumab; 616.994005
• DOI: 10.1002/cam4.5057
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established. To address this, we retrospectively assess the treatment outcomes and duration of pembrolizumab for patients whose best response was complete response (CR) or partial response (PR) in a Japanese nationwide cohort of platinum‐refractory metastatic urothelial carcinoma. Of 203 patients whose best response was CR or PR, 83 patients discontinued pembrolizumab before progression. The median pembrolizumab treatment duration was 6.9 months. The 2‐year relapse‐free survival (RFS), treatment‐free survival, and OS rates after discontinuation were 49.0%, 57.4%, and 74.5%, respectively. CR, higher hemoglobin levels, and a better Eastern Cooperative Oncology Group performance status at the time of discontinuation were associated with significantly better RFS. Pembrolizumab was re‐administered to 12 patients. Pembrolizumab re‐challenge resulted in CR, PR, stable disease, and progressive disease in six, three, two, and one patient, respectively. Propensity score‐matched landmark analysis revealed no significant OS difference between patients who continued or discontinued pembrolizumab at 6, 12, and 18 months ( p = 0.91, 0.99, and 0.25, respectively). Our findings demonstrated that patients with objective responses had favorable survival outcomes and suggested that pembrolizumab could be discontinued safely in this population. This study should drive further efforts to optimize the treatment duration for pembrolizumab responders. Abstract : Favorable relapse‐free survival was observed after pembrolizumab discontinuation in patients with urothelial carcinoma, especially in those with complete responses, higher hemoglobin levels, and better ECOG‐PS at the time of discontinuation. Re‐administration upon progression was effective in 90.9% of the patients, and no difference in overall survival was observed between the patients who continued or discontinued treatment after complete or partial responses.